Evidence map›Paper›PMID 38589558›Full record

ArticleArchives of toxicology2024

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2.

Sara Ahmed Eltayeb, Julia M Dressler, Lukas Schlatt, Moritz Pernecker, Ute Neugebauer, Uwe Karst, Giuliano Ciarimboli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara Ahmed EltayebMedizinische Klinik D, Experimentelle Nephrologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1/A14, 48149, Münster, Germany.
Julia M DresslerInstitut Für Anorganische Und Analytische Chemie, Universität Münster, Münster, Germany.
Lukas SchlattInstitut Für Anorganische Und Analytische Chemie, Universität Münster, Münster, Germany.
Moritz PerneckerMedizinische Klinik D, Experimentelle Nephrologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1/A14, 48149, Münster, Germany.
Ute NeugebauerMedizinische Klinik D, Experimentelle Nephrologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1/A14, 48149, Münster, Germany.
Uwe KarstInstitut Für Anorganische Und Analytische Chemie, Universität Münster, Münster, Germany.
Giuliano CiarimboliMedizinische Klinik D, Experimentelle Nephrologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1/A14, 48149, Münster, Germany. gciari@uni-muenster.de.ORCID 0000-0002-4365-3656

Funding

Deutsche Forschungsgemeinschaft CI107/11-1-2Deutsche Forschungsgemeinschaft CI107/14-1
6 · The paper itself

Abstract

Oxaliplatin (OHP) is effective in colorectal cancer treatment but induces peripheral neurotoxicity (OHP-induced peripheral neurotoxicity, OIPN), diminishing survivor quality of life. Organic cation transporter 2 (OCT2) is a key OHP uptake pathway in dorsal root ganglia. Competing for OCT2-mediated OHP uptake, such as with the tyrosine kinase inhibitor dasatinib, may mitigate OHP side effects. We investigated OHP and dasatinib interaction with OCT2 in human embryonic kidney 293 (HEK293) cells expressing OCT2 within a 10

Indexed as

Antineoplastic AgentsDasatinibOrganic Cation Transporter 2OxaliplatinProtein Kinase InhibitorsDrug InteractionsHEK293 CellsHumansPyridinium CompoundsTyrosine Kinase Inhibitors4-(4-dimethylaminostyryl)-1-methylpyridiniumAntineoplastic AgentsDasatinibOrganic Cation Transporter 2OxaliplatinProtein Kinase InhibitorsPyridinium CompoundsSLC22A2 protein, humanTyrosine Kinase InhibitorsDasatinibOxaliplatinPeripheral neurotoxicityTransporters

Identifiers

PMID38589558
PMCPMC11169033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.